By Christopher P. Singer --
Luminex Corporation announced that it received a non-exclusive license from Johns Hopkins University with rights to use the University's patented cystic fibrosis (CF) genetic markers. CF is a chronic autosomal recessive disorder affecting the lungs and digestive tract caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
The license rights apply to technology that is included in the Tag-It® Cystic Fibrosis Kit from Luminex Molecular Diagnostics (formerly Tm Bioscience). The Tag-It® technology aids diagnosis and screening of CF in newborns, children, and can be used to determine whether an adult is a carrier of CF. The license from Johns Hopkins provides the rights to four mutations (549N, 551D, 553X, and 559T) which are included in the Cystic Fibrosis Kit, and covers two mutations (551D, 553X) in a screening panel of 23 cystic fibrosis gene mutations.
Specific terms of the license agreement were not disclosed in Luminex's press release.
Comments